20 Jul NeoClone Biotechnology awarded $250K for ovarian cancer test
Madison, Wis. – NeoClone Biotechnology has been awarded $250,000 in two Small Business Innovation Research grants that will enable the company to expand its development of a test that could improve the detection of ovarian cancer.
Funding came from the National Cancer Institute, which is part of the National Institutes of Health. It will allow NeoClone, which produces monoclonal antibody products used by researchers, to expand ongoing work funded by a previous SBIR grant.
NeoClone, which has received several SBIR grants in the past year, has developed a patented technology to challenge traditional market approaches for antibody development. The company has developed a way to produce monoclonal antibodies in an accelerated time frame, and it can produce antibodies that bind to a specific substance in the disease detection process. The antibodies bind to molecules associated with various diseases, including several forms of cancer.
• NeoClone gets $750K for ovarian cancer detection
• Wisconsin firms urged to pursue federal SBIR dollars
• Can sales outsourcing grow Wisconsin biotechs?